1
|
Nwosu OI, Jones AJ, Alwani M, Einhorn LH, Moore MG, Mantravadi AV. Surgical Management of Cervical Non-seminomatous Germ Cell Tumor Metastases. Laryngoscope 2021; 131:1528-1534. [PMID: 33421136 DOI: 10.1002/lary.29364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 12/18/2020] [Indexed: 11/08/2022]
Abstract
OBJECTIVE/HYPOTHESIS Testicular cancer is the most common malignancy of young males. Limited reports describe perioperative and long-term outcomes after surgical resection of metastatic, cervical, non-seminomatous germ cell tumors (NSGCT). The objective of this study was to investigate the effectiveness and safety of cervical lymphadenectomy in the management of metastatic NSGCT. STUDY DESIGN Retrospective case series. METHODS A single institution, retrospective review from 1998 to 2020 of patients with metastatic NSGCT who underwent cervical lymphadenectomy was conducted. Clinicopathological, surgical, and postoperative data were collected and analyzed. RESULTS Sixty-eight predominantly white (91.0%) male patients with mean age 33.0 ± 11.3 years were included. Most (82.2%) presented with stage III disease at initial diagnosis. All patients had undergone primary platinum-based chemotherapy 1.0 to 22.7 months prior to selective ND. Surgery mainly involved nodal levels III (67.6%), IV (92.6%) and/or Vb (77.9%) and was frequently performed with concomitant thoracoabdominal NSGCT resections (63.2%). Cervical specimens predominantly revealed mature teratoma (83.8%) as solitary (69.1%) or component of mixed (14.7%) NSGCT. Ten (14.7%) perioperative complications occurred as vocal cord paresis (n = 6) from thoracic surgery and chyle leakage (n = 4). All resolved conservatively except two vocal cord paralyzes that required surgical repair due to tumor involvement of vagus nerve. Six instances of cervical recurrence occurred at median 12.5 (range, 5.8-38.6) months from ND, all re-demonstrating purely mature teratoma. The two-year cervical, non-cervical, and overall recurrence-free survivals were 83%, 55%, and 55%, respectively. Two-year disease-free and overall survivals were both 93%. CONCLUSIONS Selective neck dissection is a safe, effective method for managing cervical NSGCT metastases. LEVEL OF EVIDENCE 4 Laryngoscope, 131:1528-1534, 2021.
Collapse
Affiliation(s)
- Obi I Nwosu
- Department of Otolaryngology Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A
| | - Alexander J Jones
- Department of Otolaryngology Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A
| | - Mohamedkazim Alwani
- Department of Otolaryngology Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A
| | - Lawrence H Einhorn
- Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A
| | - Michael G Moore
- Department of Otolaryngology Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A
| | - Avinash V Mantravadi
- Department of Otolaryngology Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A
| |
Collapse
|
2
|
Sadler KA, Hanna C, Melia L, White J. Very unusual case of a primary sinonasal germ cell tumour. BMJ Case Rep 2020; 13:13/2/e232288. [PMID: 32060110 DOI: 10.1136/bcr-2019-232288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Sinonasal malignancies are a very rare diagnosis. We present a unique case of a 32-year-old man who presented with symptoms of worsening sinusitis and periorbital cellulitis. Investigation found a sinonasal malignancy and pathology confirmed this to be a primary germ cell tumour. The patient was managed with chemotherapy, surgery and consolidation radiotherapy and has remained well to date. This case report outlines an unusual presentation and diagnostic challenge for the primary care physician, ear, nose and throat surgeon, pathologist and oncologist with review of the surrounding literature.
Collapse
Affiliation(s)
- Katie Ann Sadler
- Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.,University of Glasgow Faculty of Medicine, Glasgow, UK
| | - Catherine Hanna
- University of Glasgow Faculty of Medicine, Glasgow, UK.,Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Louise Melia
- ENT Department, Queen Elizabeth University Hospital, Glasgow, UK
| | - Jeff White
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| |
Collapse
|
3
|
Patrikidou A, Chaigneau L, Isambert N, Kitikidou K, Shanley R, Ray-Coquard I, Valentin T, Malivoir B, Laigre M, Bay JO, Moureau-Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Guillemet C, Duffaud F, Hügli A, Le Pechoux C, Dhermain F, Blay JY, Sperduto PW, Le Cesne A. Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). BMC Cancer 2020; 20:117. [PMID: 32050939 PMCID: PMC7014599 DOI: 10.1186/s12885-020-6548-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Accepted: 01/16/2020] [Indexed: 01/13/2023] Open
Abstract
Abstract Background Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases. Methods We performed a multicentre analysis of a national group of expert sarcoma tertiary centres (French Sarcoma Group, GSF-GETO) with the participation of one Canadian and one Swiss centre. The study cohort included adult patients with a diagnosis of a bone or soft tissue sarcoma presenting parenchymal or meningeal brain metastases, managed between January 1992 and March 2012. We assessed the validity of the original GPA index in this patient population and developed a disease-specific Sarcoma-GPA index. Results The original GPA index is not prognostic for sarcoma brain metastasis patients. We have developed a dedicated Sarcoma-GPA index that identifies a sub-group of patients with particularly favourable prognosis based on histology, number of brain lesions and performance status. Conclusions The Sarcoma-GPA index provides a novel tool for sarcoma oncologists to guide clinical decision-making and outcomes research.
Collapse
Affiliation(s)
- Anna Patrikidou
- Gustave Roussy Cancer Campus, Villejuif, France. .,Present Address: Sarah Cannon Research Institute and UCL Cancer Institute & University College London Hospitals, 93 Harley Street, London W1G 6AD, UK.
| | | | | | | | - Ryan Shanley
- Gamma Knife Center, University of Minnesota, Minneapolis, MN, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Paul W Sperduto
- Gamma Knife Center, University of Minnesota, Minneapolis, MN, USA
| | | |
Collapse
|
4
|
Zhou RB, Lu XL, Zhang CY, Yin DC. RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection. Oncotarget 2017; 8:22235-22250. [PMID: 28118608 PMCID: PMC5400660 DOI: 10.18632/oncotarget.14755] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2016] [Accepted: 01/10/2017] [Indexed: 12/14/2022] Open
Abstract
RNA binding motif 3 (RBM3) is a highly conserved cold-induced RNA binding protein that is transcriptionally up-regulated in response to harsh stresses. Featured as RNA binding protein, RBM3 is involved in mRNA biogenesis as well as stimulating protein synthesis, promoting proliferation and exerting anti-apoptotic functions. Nowadays, accumulating immunohistochemically studies have suggested RBM3 function as a proto-oncogene that is associated with tumor progression and metastasis in various cancers. Moreover, emerging evidences have also indicated that RBM3 is equally effective in neuroprotection. In the present review, we provide an overview of current knowledge concerning the role of RBM3 in various cancers and neuroprotection. Additionally, its potential roles as a promising diagnostic marker for cancer and a possible therapeutic target for neuro-related diseases are discussed.
Collapse
Affiliation(s)
- Ren-Bin Zhou
- Key Laboratory for Space Bioscience & Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, PR China
| | - Xiao-Li Lu
- Key Laboratory for Space Bioscience & Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, PR China
| | - Chen-Yan Zhang
- Key Laboratory for Space Bioscience & Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, PR China
| | - Da-Chuan Yin
- Key Laboratory for Space Bioscience & Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi, PR China
| |
Collapse
|
5
|
Nakamura T. Editorial Comment from Dr Nakamura to Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor. Int J Urol 2015; 22:928. [PMID: 26153458 DOI: 10.1111/iju.12871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Terukazu Nakamura
- Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
| |
Collapse
|
6
|
Direct Comparison of Logistic Regression and Recursive Partitioning to Predict Lymph Node Metastasis in Endometrial Cancer. Int J Gynecol Cancer 2015; 25:1037-43. [DOI: 10.1097/igc.0000000000000451] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
ObjectiveThe purpose was to compare logistic regression model (LRM) and recursive partitioning (RP) to predict lymph node metastasis in early-stage endometrial cancer.Methods/MaterialsThree models (1 LRM and 2 RP, a simple and a complex) were built in a same training set extracted from the Surveillance, Epidemiology, and End Results database for 18,294 patients who underwent hysterectomy and lymphadenectomy for stage I or II endometrial cancer. The 3 models were validated in a same validation set of 499 patients. Model performance was quantified with respect to discrimination (evaluated by the areas under the receiver operating characteristics curves) and calibration.ResultsIn the training set, the areas under the receiver operating characteristics curves were similar for LRM (0.80 [95% confidence interval [CI], 0.79–0.81]) and the complex RP model (0.79 [95% CI, 0.78–0.80]) and higher when compared with the simple RP model (0.75 [95% CI, 0.74–0.76]). In the validation set, LRM (0.77 [95% CI, 0.75–0.79]) outperformed the simple RP model (0.72 [95% CI, 0.70–0.74]). The complex RP model had good discriminative performances (0.75 [95% CI, 0.73–0.77]). Logistic regression model also outperformed the simple RP model in terms of calibration.ConclusionsIn these real data sets, LRM outperformed the simple RP model to predict lymph node metastasis in early-stage endometrial cancer. It is therefore more suitable for clinical use considering the complexity of an RP complex model with similar performances.
Collapse
|
7
|
Kojima T, Kawai K, Tsuchiya K, Abe T, Shinohara N, Tanaka T, Masumori N, Yamada S, Arai Y, Narita S, Tsuchiya N, Habuchi T, Nishiyama H. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor. Int J Urol 2015; 22:923-7. [PMID: 26094715 DOI: 10.1111/iju.12844] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Accepted: 05/24/2015] [Indexed: 12/23/2022]
Abstract
OBJECTIVES To clarify the significance of the International Germ Cell Cancer Collaborative Group classification in the 2000s, especially in intermediate- and poor-prognosis testicular germ cell tumor in Japan. METHODS We retrospectively analyzed 117 patients with intermediate- and poor-prognosis testicular non-seminomatous germ cell tumor treated at five university hospitals in Japan between 2000 and 2010. Data collected included age, levels of tumor markers, spread to non-pulmonary visceral metastases, treatment details and survival. RESULTS The median follow-up period of all patients was 57 months. A total of 50 patients (43%) were classified as having intermediate prognosis, and 67 patients (57%) as poor prognosis according to the International Germ Cell Cancer Collaborative Group classification. As first-line chemotherapy, 92 patients (79%) received bleomycin, etoposide and cisplatin. Of all patients, 74 patients (63%) received second-line chemotherapy. The most commonly used second-line chemotherapy regimens were a combination of taxanes, ifosfamide and platinum in 49 cases (66%). Overall, 33 patients (28%) received third-line chemotherapy. A total of 88 patients (75%) underwent post-chemotherapy surgery. The 5-year overall survival for intermediate (n = 50) and poor prognosis (n = 67) was 89% and 83% (P = 0.21), respectively. In poor prognosis patients, patients with two or more risk factors (any of high lactic dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin levels, and presence of non-pulmonary visceral metastases) had significantly worse survival than those with only one risk factor (71% and 91%, respectively, P = 0.01). CONCLUSIONS The 5-year overall survivals of poor-prognosis testicular non-seminomatous germ cell tumor patients reached 83%. Further stratification of poor-prognosis patients based on a number of risk factors has the potential to further identify those with poorer prognosis.
Collapse
Affiliation(s)
- Takahiro Kojima
- Department of Urology, University of Tsukuba, Tsukuba, Japan
| | - Koji Kawai
- Department of Urology, University of Tsukuba, Tsukuba, Japan
| | - Kunihiko Tsuchiya
- Department of Urology, Graduate School of Medical Sciences, Hokkaido University, Sapporo, Japan
| | - Takashige Abe
- Department of Urology, Graduate School of Medical Sciences, Hokkaido University, Sapporo, Japan
| | - Nobuo Shinohara
- Department of Urology, Graduate School of Medical Sciences, Hokkaido University, Sapporo, Japan
| | - Toshiaki Tanaka
- Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Naoya Masumori
- Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shigeyuki Yamada
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Yoichi Arai
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | | | | | | | | |
Collapse
|
8
|
Dutta DK, Gwebu KL, Wang J. Strategy and Vendor Selection in IT Outsourcing: Is there a Method in the Madness? JOURNAL OF GLOBAL INFORMATION TECHNOLOGY MANAGEMENT 2014. [DOI: 10.1080/1097198x.2011.10856535] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
9
|
Yetisyigit T, Babacan N, Urun Y, Seber ES, Cihan S, Arpaci E, Yildirim N, Aksoy S, Budakoglu B, Zengin N, Oksuzoglu B, Yalcin BC, Alkis N. Predictors of Outcome in Patients with Advanced Nonseminomatous Germ Cell Testicular Tumors. Asian Pac J Cancer Prev 2014; 15:831-5. [DOI: 10.7314/apjcp.2014.15.2.831] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
10
|
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin N, Mehta M. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2011; 30:419-25. [PMID: 22203767 DOI: 10.1200/jco.2011.38.0527] [Citation(s) in RCA: 1015] [Impact Index Per Article: 78.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
PURPOSE Our group has previously published the Graded Prognostic Assessment (GPA), a prognostic index for patients with brain metastases. Updates have been published with refinements to create diagnosis-specific Graded Prognostic Assessment indices. The purpose of this report is to present the updated diagnosis-specific GPA indices in a single, unified, user-friendly report to allow ease of access and use by treating physicians. METHODS A multi-institutional retrospective (1985 to 2007) database of 3,940 patients with newly diagnosed brain metastases underwent univariate and multivariate analyses of prognostic factors associated with outcomes by primary site and treatment. Significant prognostic factors were used to define the diagnosis-specific GPA prognostic indices. A GPA of 4.0 correlates with the best prognosis, whereas a GPA of 0.0 corresponds with the worst prognosis. RESULTS Significant prognostic factors varied by diagnosis. For lung cancer, prognostic factors were Karnofsky performance score, age, presence of extracranial metastases, and number of brain metastases, confirming the original Lung-GPA. For melanoma and renal cell cancer, prognostic factors were Karnofsky performance score and the number of brain metastases. For breast cancer, prognostic factors were tumor subtype, Karnofsky performance score, and age. For GI cancer, the only prognostic factor was the Karnofsky performance score. The median survival times by GPA score and diagnosis were determined. CONCLUSION Prognostic factors for patients with brain metastases vary by diagnosis, and for each diagnosis, a robust separation into different GPA scores was discerned, implying considerable heterogeneity in outcome, even within a single tumor type. In summary, these indices and related worksheet provide an accurate and facile diagnosis-specific tool to estimate survival, potentially select appropriate treatment, and stratify clinical trials for patients with brain metastases.
Collapse
Affiliation(s)
- Paul W Sperduto
- University of Minnesota Gamma Knife, Minneapolis Radiation Oncology, MN, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2011; 82:2111-7. [PMID: 21497451 DOI: 10.1016/j.ijrobp.2011.02.027] [Citation(s) in RCA: 249] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2010] [Revised: 02/08/2011] [Accepted: 02/11/2011] [Indexed: 01/09/2023]
Abstract
PURPOSE The diagnosis-specific Graded Prognostic Assessment (GPA) was published to clarify prognosis for patients with brain metastases. This study refines the existing Breast-GPA by analyzing a larger cohort and tumor subtype. METHODS AND MATERIALS A multi-institutional retrospective database of 400 breast cancer patients treated for newly diagnosed brain metastases was generated. Prognostic factors significant for survival were analyzed by multivariate Cox regression and recursive partitioning analysis (RPA). Factors were weighted by the magnitude of their regression coefficients to define the GPA index. RESULTS Significant prognostic factors by multivariate Cox regression and RPA were Karnofsky performance status (KPS), HER2, ER/PR status, and the interaction between ER/PR and HER2. RPA showed age was significant for patients with KPS 60 to 80. The median survival time (MST) overall was 13.8 months, and for GPA scores of 0 to 1.0, 1.5 to 2.0, 2.5 to 3.0, and 3.5 to 4.0 were 3.4 (n = 23), 7.7 (n = 104), 15.1 (n = 140), and 25.3 (n = 133) months, respectively (p < 0.0001). Among HER2-negative patients, being ER/PR positive improved MST from 6.4 to 9.7 months, whereas in HER2-positive patients, being ER/PR positive improved MST from 17.9 to 20.7 months. The log-rank statistic (predictive power) was 110 for the Breast-GPA vs. 55 for tumor subtype. CONCLUSIONS The Breast-GPA documents wide variation in prognosis and shows clear separation between subgroups of patients with breast cancer and brain metastases. This tool will aid clinical decision making and stratification in clinical trials. These data confirm the effect of tumor subtype on survival and show the Breast-GPA offers significantly more predictive power than the tumor subtype alone.
Collapse
|
12
|
|
13
|
van Dijk MR, Steyerberg EW, Habbema JDF. A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients. BMC Med Inform Decis Mak 2008; 8:1. [PMID: 18171485 PMCID: PMC2266916 DOI: 10.1186/1472-6947-8-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2006] [Accepted: 01/03/2008] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Classification systems may be useful to direct more aggressive treatment to cancer patients with a relatively poor prognosis. The definition of 'poor prognosis' often lacks a formal basis. We propose a decision analytic approach to weigh benefits and harms explicitly to define the treatment threshold for more aggressive treatment. This approach is illustrated by a case study in advanced testicular cancer, where patients with a high risk of mortality under standard treatment may be eligible for high-dose chemotherapy with stem cell support, which is currently defined by the IGCC classification. METHODS We used published literature to estimate the benefit and harm of high-dose chemotherapy (HD-CT) versus standard-dose chemotherapy (SD-CT) for patients with advanced non-seminomatous germ cell cancer. Benefit and harm were defined as the reduction and increase in absolute risk of mortality due to HD-CT respectively. Harm included early and late treatment related death, and treatment related morbidity (weighted by 'utility'). RESULTS We considered a conservative and an optimistic benefit of 30 and 40% risk reduction respectively. We estimated the excess treatment related mortality at 2%. When treatment related morbidity was taken into account, the harm of HD-CT increased to 5%. With a relative benefit of 30% and harm of 2 or 5%, HD-CT might be beneficial for patients with over 7 or 17% risk of cancer specific mortality with SD chemotherapy, while with a relative benefit of 40% HD-CT was beneficial over 5 and 12.5% risk respectively. Compared to the IGCC classification 14% of the patients would receive more aggressive treatment, and 2% less intensive treatment. CONCLUSION Benefit and harm can be used to define 'poor prognosis' explicitly for non-seminomatous germ cell cancer patients who are considered for high-dose chemotherapy. This approach can readily be adapted to new results and extended to other cancers to define candidates for more aggressive treatments.
Collapse
Affiliation(s)
- Merel R van Dijk
- Department of Public Health, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
| | | | | |
Collapse
|
14
|
Mathers MJ, Lazica DA, Klotz T, Sommer F, Roth S. [Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder]. Urologe A 2007; 46:636-41. [PMID: 17487469 DOI: 10.1007/s00120-007-1353-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
It is generally agreed upon that patients require a caring as well as careful medical follow-up after cancer treatment. The goal of secondary prevention is to recognize a recurrence at an early stage and to use the curative chance while the tumor mass is still small. There is evidence of a medically effective and successful follow-up for tumors of the testicle and the bladder. For quality reasons, these follow-up regimes should be adhered to for quality reasons. In other diseases, e.g., renal cell carcinoma, prospective randomized studies are missing which demonstrate the effectiveness of follow-ups. In these cases asymptomatic patients should be stratified to individualized follow-up care.
Collapse
Affiliation(s)
- M J Mathers
- Urologische Gemeinschaftspraxis, Kooperationspraxis der Klinik für Urologie und Kinderurologie, Klinikum Wuppertal, Universität Witten/Herdecke, Fastenrathstrasse 1, 42853 Remscheid, Germany.
| | | | | | | | | |
Collapse
|
15
|
Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol 2006; 103:912-8. [PMID: 16837029 DOI: 10.1016/j.ygyno.2006.05.043] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2006] [Revised: 05/18/2006] [Accepted: 05/24/2006] [Indexed: 02/07/2023]
Abstract
PURPOSE Lactate dehydrogenase (LDH-5) is a major lactate dehydrogenase isoenzyme catalyzing the transformation of pyruvate to lactate for anaerobic acquisition energy. In this study, the expression of LDH-5 was assessed in the normal and malignant endometrium. Its role in prognosis and tumor angiogenesis and hypoxia was also examined. EXPERIMENTAL DESIGN Tissue specimens from 68 patients with clinical stage I endometrial adenocarcinoma of the endometrioid cell type and 20 samples from normally cycling endometrium were investigated immunohistochemically for the expression of LDH-5. The vascular density and the expression of angiogenesis/hypoxia-related proteins (VEGF, HIF1alpha, HIF2alpha, phosphorylated VEGFR2/KDR, VEGF/KDR complex) were also assessed. RESULTS Unlike other normal epithelia, the glandular endometrial cells consistently expressed LDH-5 suggesting a role of this enzyme in the normal menstrual cycle. Endometrial adenocarcinomas displayed LDH-5 expression in 31/68 (45.5%) cases with those having a high LDH-5 expression being connected with a low lymphocytic response; this may suggest an important role of LDH-5 and, presumably, lactate release in tumor escape from host immuno-surveillance. More importantly, LDH-5 was significantly associated with the expression of phosphorylated VEGFR2/KDR receptors in cancer cells and tumor-associated vasculature. LDH-5 was one of the most powerful and independent prognostic variables. CONCLUSIONS LDH-5 expression is an independent prognostic marker in endometrial cancer, linked with impaired host immune response and activation of VEGFR2/KDR receptors in both cancer cells and tumor-associated vasculature. Adjuvant radio-chemotherapy may, therefore, be useful in these cases, while the administration of VEGF- tyrosine kinase receptor inhibitors emerges as a therapeutic option.
Collapse
Affiliation(s)
- Alexandra Giatromanolaki
- Department of Pathology, Democritus University of Thrace, Medical School, PO Box 12, Alexandroupolis 68100, Greece, and John Radcliffe Hospital, Oxford, UK.
| | | | | | | | | | | |
Collapse
|
16
|
Kawai K, Hinotsu S, Oikawa T, Sekido N, Hattori K, Miyanaga N, Hasegawa Y, Kojima H, Shimazui T, Akaza H. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor. Jpn J Clin Oncol 2006; 36:723-30. [PMID: 17082218 DOI: 10.1093/jjco/hyl102] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Incidence of testicular cancer is low in Japan. Recent investigations showed that the outcome of metastatic testicular cancer is associated with the experience of the treatment institution. Objectives of the present investigation are to evaluate outcome of a single institution in Japan, and to identify prognostic factors for testicular cancer. METHODS We retrospectively analysed the outcome of 74 patients with metastatic testicular cancer who were treated at Tsukuba University Hospital (TUH) between January 1981 and January 2003. Forty-five patients (61%) were referred to the TUH for the treatment of metastatic disease. The progression-free survival (PFS) rates according to the International Germ Cell Cancer (IGCC) classification and the Indiana University classification were used to evaluate the treatment outcome. RESULTS The median follow-up period of all patients was 87 months (range, 13-260 months). Forty patients (54%) were classified as having good prognosis, 20 (27%) intermediate, and 14 (19%) poor. The overall 5- and 10-year PFS was 79 and 74%, respectively. The 5-year PFS with good, intermediate and poor prognosis was 90, 70 and 64%, respectively. There was a significant difference between the three groups (P=0.02), but the survival of the intermediate-prognosis group was not statistically different from that of the poor-prognosis group. The Indiana University classification failed to discriminate the prognoses of moderate and advanced disease, but proved to be an independent prognostic factor for progression-free survival in intermediate- and poor-prognosis patients (P=0.025, hazard ratio=5.39). CONCLUSIONS Our treatment outcome is not different from that of the institutions participating in the International Germ Cell Cancer Consensus Group (IGCCCG).
Collapse
Affiliation(s)
- Koji Kawai
- Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-City, Ibaraki 305, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006; 24:4301-8. [PMID: 16896001 DOI: 10.1200/jco.2006.05.9501] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
PURPOSE Lactate dehydrogenase 5 (LDH-5) regulates, under hypoxic conditions, the anaerobic transformation of pyruvate to lactate for energy acquisition. Several studies have shown that serum LDH may be an ominous prognostic marker in malignant tumors. The clinical significance of tissue LDH-5, however, remains largely unexplored. PATIENTS AND METHODS We investigated the immunohistochemical expression of LDH-5 in a series of 128 stage II/III colorectal adenocarcinomas treated with surgery alone. In addition, markers of tumor hypoxia (hypoxia-inducible factor 1 alpha [HIF1alpha]), angiogenesis (vascular endothelial growth factor [VEGF] and phosporylated kinase domain receptor [pKDR]/flk-1 receptor) and the tumor vascular density (CD31 positive standard vascular density [sVD] and pKDR positive activated vascular density [aVD]) were assessed. RESULTS The expression of LDH-5, together with that of HIF1alpha and pKDR, was both nuclear and cytoplasmic. Assessment, with minimal interobserver variability, was achieved using a previously described scoring system. LDH-5 was significantly associated with HIF1alpha (P = .01), aVD (P = .001) and, particularly, with pKDR expression in cancer cells (P = .0001). Tissue LDH-5 expression was linked with elevated serum LDH levels, but serum levels failed to reflect tissue expression in 71% of LDH-5 positive cases. In univariate analysis tissue LDH-5 was associated with poor survival (P = .0003, HR 15.1), whereas in multivariate analysis this isoenzyme was the strongest independent prognostic factor (P = .0009). VEGF, pKDR, aVD, sVD and vascular invasion were all significantly related to unfavorable prognosis. CONCLUSION The immunohistochemical assessment of tissue LDH-5 and pKDR provides important prognostic information in operable colorectal cancer. The strong association between LDH-5 and pKDR expression would justify their use as surrogate markers to screen patients for tyrosine kinase inhibitor therapy.
Collapse
|
18
|
van Dijk MR, Steyerberg EW, Stenning SP, Habbema JDF. Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values. J Clin Epidemiol 2006; 59:246-53. [PMID: 16488355 DOI: 10.1016/j.jclinepi.2005.08.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2004] [Revised: 07/04/2005] [Accepted: 08/22/2005] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVE The International Germ Cell Consensus (IGCC) classification defines good, intermediate, and poor prognosis groups among patients with nonseminomatous germ cell cancer. In the database used to develop the IGCC classification (n = 5,202), >40% of patients were excluded because of missing values (n = 2,154). We looked for effects of this exclusion on survival estimates in the three IGCC prognosis groups. STUDY DESIGN AND SETTING We imputed missing values using a multiple imputation procedure. The IGCC classification was applied to patients with complete data (n = 3,048) and with imputed data (n = 2,154), and 5-year survival was calculated for each prognosis group. RESULTS Patients with missing values had a lower 5-year survival than those without missing values: 76% vs. 82%. Five-year survival in the complete and imputed data samples was 92% and 87% for the good prognosis groups and 80% and 70% for the intermediate prognosis groups, whereas 5-year survival for the poor prognosis groups in both samples was similar (50% and 47%, respectively). This difference in survival was largely explained by a higher proportion of missing values among patients treated before 1985, who had a worse survival than patients treated after 1985. CONCLUSION Multiple imputation of the missing values led to lower survival estimates across the IGCC prognosis groups, compared with estimates based on the complete data. Although imputation of missing values gives statistically better survival estimates, adjustments for year of treatment are necessary to make the estimates applicable to currently diagnosed patients with testicular cancer.
Collapse
Affiliation(s)
- Merel R van Dijk
- Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Ee 20.87, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
| | | | | | | |
Collapse
|
19
|
Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen. Cancer 2006; 107:1503-10. [PMID: 16944534 DOI: 10.1002/cncr.22181] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND The presence of viable tumor in the surgical specimen after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) is associated with an increased risk of disease progression. The objective of this study was to determine whether the presence of viable tumor in the surgical specimen could be predicted. METHODS Between 1980 and 2003, 236 patients underwent PC-RPLND for clinical Stage IIA or III nonseminomatous germ cell tumors (NSGCT). The authors retrospectively reviewed the medical records of those patients for pertinent clinical and treatment-related outcomes. A multivariate logistic regression analysis was used to evaluate whether clinical parameters were capable of predicting the presence of viable tumor in the surgical specimen. RESULTS International Germ Cell Consensus Classification (IGCCC) risk categories could be assigned to 218 patients, with 101 patients in the good-risk category, 32 patients in the intermediate-risk category, and 85 patients in the poor-risk category. The incidence of viable tumor in the good-risk, intermediate-risk, and poor-risk categories was similar (17.8%, 15.6%, and 15.3%, respectively); however, the risk categories predicted disease-specific and recurrence-free survival (P = .022 and P < .0001, respectively). On multivariate analysis, an elevated serum alpha-fetoprotein (AFP) level prior to PC-RPLND (P = .05) and the size of the retroperitoneal mass on pathology review (P = .02) were predictive of viable tumor in the surgical specimen. CONCLUSIONS Although IGCCC risk categories were correlated with disease-related outcomes, the risk groups had similar incidences of viable tumor. Elevated serum AFP levels prior to surgery and the size of the retroperitoneal mass in the resected specimen may help to predict viable tumor in the PC-RPLND specimen.
Collapse
Affiliation(s)
- Philippe E Spiess
- Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
Patients with germ cell tumours of the testis can have an extremely favourable chance of cure when compared to other malignancies. Therapeutic problems may arise with recurrent disease. High tumour burden can result when relapses are diagnosed too late and the prognosis will deteriorate, consecutively, even in spite of intensified therapeutic endeavours. Apart from early detection of recurrent disease, the follow-up schedule of germ cell cancer aims to identify and manage treatment-related morbidities, e.g. vascular problems and second neoplasms, respectively. Follow-up examinations should be tailored to the individual situation taking into account the particular risk of relapse based on histology, stage and treatment previously applied. In light of the rarity of the disease and according to the complexity of managing this malignancy, follow-up should be conducted by particularly experienced institutions.
Collapse
Affiliation(s)
- T S Pottek
- Abteilung Urologie, Bundeswehrkrankenhaus, Hamburg.
| | | |
Collapse
|
21
|
Götz HM, van Bergen JEAM, Veldhuijzen IK, Broer J, Hoebe CJPA, Steyerberg EW, Coenen AJJ, de Groot F, Verhooren MJC, van Schaik DT, Richardus JH. A prediction rule for selective screening of Chlamydia trachomatis infection. Sex Transm Infect 2005; 81:24-30. [PMID: 15681717 PMCID: PMC1763735 DOI: 10.1136/sti.2004.010181] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Screening for Chlamydia trachomatis infections is aimed at the reduction of these infections and subsequent complications. Selective screening may increase the cost effectiveness of a screening programme. Few population based systematic screening programmes have been carried out and attempts to validate selective screening criteria have shown poor performance. This study describes the development of a prediction rule for estimating the risk of chlamydial infection as a basis for selective screening. METHODS A population based chlamydia screening study was performed in the Netherlands by inviting 21,000 15-29 year old women and men in urban and rural areas for home based urine testing. Multivariable logistic regression was used to identify risk factors for chlamydial infection among 6303 sexually active participants, and the discriminative ability was measured by the area under the receiver operating characteristic curve (AUC). Internal validity was assessed with bootstrap resampling techniques. RESULTS The prevalence of C trachomatis (CT) infection was 2.6% (95% CI 2.2 to 3.2) in women and 2.0% (95% CI 1.4 to 2.7) in men. Chlamydial infection was associated with high level of urbanisation, young age, Surinam/Antillian ethnicity, low/intermediate education, multiple lifetime partners, a new contact in the previous two months, no condom use at last sexual contact, and complaints of (post)coital bleeding in women and frequent urination in men. A prediction model with these risk factors showed adequate discriminative ability at internal validation (AUC 0.78). CONCLUSION The prediction rule has the potential to guide individuals in their choice of participation when offered chlamydia screening and is a promising tool for selective CT screening at population level.
Collapse
Affiliation(s)
- H M Götz
- Municipal Health Service Rotterdam, Department Infectious Diseases, PO Box 70032, 3000 LP Rotterdam, the Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|